This paper outlines strategies for the non-clinical and clinical evaluation of the abuse potential of psychedelics, ie serotonergic hallucinogens and entactogens for new drug applications to the FDA and scheduling recommendations. 

We are pleased to announce publication of this article by the Journal of Psychopharmacology. The paper outlines strategies for the non-clinical and clinical evaluation of the abuse potential of psychedelics, ie serotonergic hallucinogens such as psilocybin and entactogens such as MDMA for new drug applications to the FDA and scheduling recommendations. It was co-authored by David Heal and Sharon Smith of DevelRx in collaboration with Jack Henningfield and Judy Ashworth of 

Further details of the publication are given 

 if you would like to discuss our services for evaluating the abuse potential of psychedelic drugs. These include 8-factor analyses for new drug applications.

Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective